World Journal of Pharmaceutical
and Medical Research

( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical and Medical Research and Technology
An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)
ISSN 2455-3301
IMPACT FACTOR: 6.842

ICV : 78.6

World Journal of Pharmaceutical and Medical Research (WJPMR) has indexed with various reputed international bodies like : Google Scholar , Index Copernicus , SOCOLAR, China , Indian Science Publications , Cosmos Impact Factor , Research Bible, Fuchu, Tokyo. JAPAN , Scientific Indexing Services (SIS) , UDLedge Science Citation Index , International Impact Factor Services , International Society for Research Activity (ISRA) Journal Impact Factor (JIF) , International Innovative Journal Impact Factor (IIJIF) , Scientific Journal Impact Factor (SJIF) , Global Impact Factor (In Process) , Digital Online Identifier-Database System (DOI-DS) , Science Library Index, Dubai, United Arab Emirates , Eurasian Scientific Journal Index (ESJI) , International Scientific Indexing, (ISI) UAE , IFSIJ Measure of Journal Quality , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database , Academia , 

Abstract

BETRIXABAN – THE FIRST AND ONLY ORAL ANTICOAGULANT APPROVED FOR VTE

Dr. Haritha Themagepalli*

ABSTRACT

Venous Thromboembolism (VTE) is one of the leading causes of preventable death. Though many drugs are already available for the treatment, all of them were non-oral with severe toxicities in renal and hepatic impaired patients. Betrixaban is a factor Xa inhibitor, orally active drug with unique characteristics like long Half-life, minimal renal excretion, minimal hepatic metabolism. This article provided review on all aspects of Betrixaban including its mechanism of action, its pharmacokinetics, pharmacodynamics, pre-clinical studies, clinical phases of this drug with a note on its safety and efficacy concerns on every phase and comparison with other existing treatments for VTE like Enoxaparin, Warfarin, and the emergence of extended duration thromboprophylaxis and its antidote Andexanet alfa.

[Full Text Article]    [Download Certificate]

Powered By WJPMR | All Right Reserved

WJPMR